SIRT | Sorafenib | P* | |||||
Parameter | SIRveNIB | SARAH | Combined | SIRveNIB | SARAH | Combined | |
N | 123 | 174 | 297 | 142 | 206 | 348 | |
ORR (CR + PR) (%) | 27 (21.9) | 32 (18.4) | 59 (19.9) | 3 (2.1) | 23 (11.2) | 26 (7.5) | <0.0001 |
DCR (CR + PR + SDis) (%) | 72 (58.5) | 115 (66.1) | 187 (63.0) | 67 (47.2) | 148 (71.8) | 215 (61.8) | 0.81 |
CR (%) | 0 (0.0) | 4 (2.3) | 4 (1.3) | 0 (0.0) | 2 (1.0) | 2 (0.6) | 0.42 |
PR (%) | 27 (21.9) | 28 (16.1) | 55 (18.5) | 3 (2.1) | 21 (10.2) | 24 (6.9) | <0.0001 |
SDis (%) | 45 (36.6) | 83 (47.7) | 128 (43.1) | 64 (45.1) | 125 (60.7) | 189 (57.3) | 0.005 |
PD (%) | 27 (21.9) | 49 (28.2) | 76 (25.6) | 41 (28.9) | 40 (19.4) | 81 (23.3) | 0.23 |
Not done/not evaluable | 24 (19.5) | 10 | 34 (11.4) | 34 (23.9) | 18 | 52 (14.9) | 0.20 |
↵* SIRT vs. sorafenib.
CR = complete response; PR = partial response; SDis = stable disease; DCR = disease control rate; ORR = objective response rate; PD = progressive disease.
Numbers (CR + PR + SDis + PD) do not add up to total number for SIRveNIB trial because of small proportion of patients with nonevaluable of missing data. SORAMIC trial is not included because tumor response was not endpoint of study.